[1]程胜君,崔家旗,杨帆.血清可溶性人凝集素样氧化低密度脂蛋白受体1与非小细胞肺癌患者病理特征的相关性分析[J].陕西医学杂志,2026,(1):125-129.[doi:DOI:10.3969/j.issn.1000-7377.2026.01.023]
　CHENG Shengjun,CUI Jiaqi,YANG Fan.Correlation analysis between serum soluble lectin-like oxidized low density lipoprotein receptor-1 and pathological characteristics of non-small cell lung cancer patients[J].,2026,(1):125-129.[doi:DOI:10.3969/j.issn.1000-7377.2026.01.023]
点击复制

血清可溶性人凝集素样氧化低密度脂蛋白受体1与非小细胞肺癌患者病理特征的相关性分析

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年1期
页码:
125-129
栏目:
临床病理
出版日期:
2026-01-05

文章信息/Info

Title:
Correlation analysis between serum soluble lectin-like oxidized low density lipoprotein receptor-1 and pathological characteristics of non-small cell lung cancer patients
作者:
程胜君; 崔家旗; 杨帆
（成都市第五人民医院病理科，四川 成都611130)
Author(s):
CHENG Shengjun; CUI Jiaqi; YANG Fan
（Department of Pathology,The Fifth People’s Hospital of Chengdu,Chengdu 611130,China）
关键词:
非小细胞肺癌; 血清可溶性人凝集素样氧化低密度脂蛋白受体1; 临床分期; 肺内转移; 分化程度; 肺外转移; 生存曲线
Keywords:
Non-small cell lung cancer; Sevum soluble lectin-like oxidized low density lipoprotein receptor-1; Clinical stage; Intra-pulmonary metastasis; Degree of differentiation; Extra-pulmonary metastasis; Survival curve
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.01.023
文献标志码:
A
摘要:
目的：探究血清可溶性人凝集素样氧化低密度脂蛋白受体1（sLOX-1）与非小细胞肺癌（NSCLC）患者病理特征的相关性。方法：选取300例非小细胞肺癌患者作为观察组，纳入健康志愿者300例作为对照组。比较两组血清sLOX-1及肿瘤标志物[神经元特异性烯醇化酶（NSE）、癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）]水平，分析NSCLC患者血清sLOX-1与肿瘤标志物NSE、CEA、CYFRA21-1水平间相关性，比较不同病理特征的NSCLC患者血清sLOX-1水平，分析NSCLC患者血清sLOX-1水平相关病理因素，并分析血清sLOX-1水平对NSCLC患者预后的影响。结果：观察组血清sLOX-1及肿瘤标志物NSE、CEA、CYFRA21-1水平均高于对照组（均P＜0.05）；Spearman相关性分析可知，NSCLC患者血清sLOX-1与肿瘤标志物NSE、CEA、CYFRA21-1水平均呈正相关（均P＜0.05）；NSCLC患者血清sLOX-1水平在临床分期、分化程度、肺内转移及肺外转移方面比较，差异有统计学意义（均P＜0.05）；多元线性回归分析显示，临床分期、肿瘤分化程度、肺内转移及肺外转移均与NSCLC患者血清sLOX-1水平有关（均P＜0.05）；300例NSCLC患者3年死亡99例，3年总生存率为67.00%。以NSCLC患者血清sLOX-1平均值为界，分为高水平亚组（＞平均值）与低水平亚组（≤平均值），高水平亚组NSCLC患者的3年生存率为53.21%，明显低于低水平亚组的81.94%（P＜0.05）。结论：NSCLC患者血清sLOX-1与其病理特征密切相关，临床分期、分化程度、肺内外转移均为血清sLOX-1水平影响因素，且临床检测血清sLOX-1水平，有助于预测NSCLC患者预后生存。
Abstract:
Objective:To explore the correlation between serum soluble lectin-like oxidized low density lipoprotein receptor-1 (sLOX-1) and the pathological characteristics of patients with non-small cell lung cancer (NSCLC).Methods：A total of 300 NSCLC patients were selected as the observation group,and 300 healthy volunteers were included as the control group.The levels of serum sLOX-1 and tumor markers [neuron-specific enolase (NSE),carcinoembryonic antigen (CEA),and cytokeratin 19 fragment (CYFRA21-1)]were compared between the two groups.The correlation between serum sLOX-1 levels and tumor markers NSE,CEA,and CYFRA21-1 levels was analyzed in NSCLC patients.The serum sLOX-1 levels were compared in NSCLC patients with different pathological characteristics.The pathological factors related to the serum sLOX-1 level were analyzed in NSCLC patients.and the impact of serum sLOX-1 levels on the prognosis of NSCLC patients was analyzed.Results:The levels of serum sLOX-1 and tumor markers NSE,CEA,and CYFRA21-1 in the observation group were higher than those in the control group (all P<0.05).Spearman correlation analysis showed that the serum sLOX-1 level in NSCLC patients was positively correlated with the levels of tumor markers NSE,CEA,and CYFRA21-1 (all P<0.05).The serum levels of sLOX-1 in NSCLC patients were compared in terms of clinical staging,degree of differentiation,pulmonary metastasis,and extrapulmonary metastasis,and the differences were statistically significant (all P<0.05).Multiple linear regression analysis showed that clinical stage,tumor differentiation,intrapulmonary metastasis,and extrapulmonary metastasis were all associated with the serum sLOX-1 level in NSCLC patients (all P<0.05).Among the 300 NSCLC patients,99 died in 3 years,and the 3-year overall survival rate was 67.00%.The NSCLC patients were divided into high-level subgroup (>average value) and low-level subgroup (≤average value) based on the average value of serum sLOX-1 in NSCLC patients.The 3-year survival rate of NSCLC patients in the high-level subgroup was 53.21%,which was significantly lower than that of the low-level subgroup (81.94%) (P<0.05).Conclusion: The serum sLOX-1 level in NSCLC patients is closely related to their pathological characteristics.Clinical stage,degree of differentiation,and intra- and extra-pulmonary metastasis are all factors that affect the level of serum sLOX-1.Clinical detection of serum sLOX-1 levels can help predict the prognosis and survival of NSCLC patients.

参考文献/References:

[1]韩鹏,张伯翔,杨艺员,等.非小细胞肺癌组织中NDUFA4L2的表达及其临床意义[J].陕西医学杂志,2025,54(4)：435-440,457.
[2]MEYER M L,FITZGERALD B G,PAZ-ARES L,et al.New promises and challenges in the treatment of advanced non-small-cell lung cancer[J].Lancet,2024,404(10454)：803-822.
[3]胡建伟,袁香坤,张永侠,等.不同消融方式联合靶向治疗对非小细胞肺癌的疗效及对患者血清指标的影响[J].陕西医学杂志,2024,53(4)：527-530.
[4]YIN S Y,YU Y,WU N,et al.Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer[J].Cell Stem Cell,2024,31(5)：717-733.
[5]ZHU L F,ZHU X Y,WU Y.Effects of glucose metabolism,lipid metabolism,and glutamine metabolism on tumor microenvironment and clinical implications[J].Biomolecules,2022,12(4)：580-587.
[6]ALANNAN M,FAYYAD-KAZAN H,TRZGUET V,et al.Targeting lipid metabolism in liver cancer[J].Biochemistry,2020,59(41)：3951-3964.
[7]LIU L L,MO M,CHEN X H,et al.Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer[J].J Exp Clin Cancer Res,2023,42(1)：85-88.
[8]NAKASHIMA-NAKASUGA C,HAZAMA S,SUZUKI N,et al.Serum LOX-1 is a novel prognostic biomarker of colorectal cancer[J].Int J Clin Oncol,2020,25(7)：1308-1317.
[9]MURDOCCA M,CAPUANO R,PUCCI S,et al.Targeting LOX-1 inhibits colorectal cancer metastasis in an animal model[J].Front Oncol,2019,9(31)：927-930.
[10]MURDOCCA M,DE MASI C,PUCCI S,et al.LOX-1 and cancer：An indissoluble liaison[J].Cancer Gene Ther,2021,28(10-11)：1088-1098.
[11]倪志强,袁正泰,段珊珊,等.氧化低密度脂蛋白受体1在胃癌组织中的表达及临床意义[J].中国医师杂志,2020,22(5)：731-735,740.
[12]解宝泉,王红阳,王袁,等.老年肺癌患者血清低密度脂蛋白与CYFRA21-1水平及其相关性分析[J].中国临床研究,2017,30(1)：23-26.
[13]何志文,王旺,张人杰,等.极低密度脂蛋白受体基因促进膀胱癌细胞迁移的作用及机制[J].中华实验外科杂志,2022,39(1)：92-94.
[14]邓青,程蔚蔚,陈岚.高密度脂蛋白胆固醇、铁蛋白、整合素α3与Ⅳ期非小细胞肺癌病理特征及患者生存预后的相关性[J].实用癌症杂志,2022,37(10)：1591-1595.
[15]郝芳芳,陈建荣,陈金亮,等.凝集素样氧化型低密度脂蛋白受体1在肿瘤中的研究进展[J].国际呼吸杂志,2020,40(22)：1751-1755.
[16]BAGHERI B,KHATIBIYAN FEYZABADI Z,NOURI A,et al.Atherosclerosis and Toll-Like Receptor4 (TLR4),Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1),and Proprotein Convertase Subtilisin/Kexin Type9 (PCSK9)[J].Mediators Inflamm,2024,11(55)：5830-5834.
[17]芦兰,王鑫,张瑞琦,等.酒精性心肌病大鼠模型中凝集素样氧化低密度脂蛋白受体-1表达与细胞凋亡相关蛋白Bax、Cleaved Caspase-3表达关系研究[J].陕西医学杂志,2022,51(10)：1201-1205.
[18]LIU J,JIN B,LU J,et al.Angiotensin Ⅱ type 2 receptor prevents extracellular matrix accumulation in human peritoneal mesothelial cell by ameliorating lipid disorder via LOX-1 suppression[J].Ren Fail,2022,44(1)：1687-1697.
[19]PUCCI S,POLIDORO C,GREGGI C,et al.Pro-oncogenic action of LOX-1 and its splice variant LOX-1δ4 in breast cancer phenotypes[J].Cell Death Dis,2019,10(2)：53-57.
[20]LI C,ZHANG J,WU H,et al.Lectin-like oxidized low-density lipoprotein receptor-1 facilitates metastasis of gastric cancer through driving epithelial-mesenchymal transition and PI3K/Akt/GSK3β activation[J].Sci Rep,2017,7(34)：4527-4535.
[21]JIANG L,JIANG S S,LIN Y B,et al.Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer[J].Oncotarget,2015,6(26)：22072-22080.
[22]ZHANG J,ZHANG L,LI C,et al.LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients[J].Cell Oncol (Dordr),2018,41(1)：73-84.
[23]吴阳,姚坚,陈金亮.基于ox-LDL/LOX-1信号通路探讨脂质代谢紊乱促进肺癌进展中的机制[J].实用医学杂志,2024,40(1)：19-24,31.
[24]KAPOOR P,DESHMUKH R.VEGF：A critical driver for angiogenesis and subsequent tumor growth：An IHC study[J].J Oral Maxillofac Pathol,2012,16(3)：330-337.
[25]LAWLER J.Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1[J].Semin Cancer Biol,2022,86(Pt 2)：126-135.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(1):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(1):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(1):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(1):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(1):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(1):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
四川省医学（青年创新）科研项目（S201149）
更新日期/Last Update: 2026-01-05